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Patient initiated outpatient follow up in rheumatoid arthritis: six
year randomised controlled trial
Sarah Hewlett, John Kirwan, Jon Pollock, Kathryn Mitchell, Maggie Hehir, Peter S Blair, David Memel, Mark G Perry
Abstract
Objectives To determine whether direct access to hospital
review initiated by patients with rheumatoid arthritis would
result in improved clinical and psychological outcome, reduced
overall use of healthcare resources, and greater satisfaction with
care than seen in patients receiving regular review initiated by a
rheumatologist.
Design Two year randomised controlled trial extended to six
years.
Setting Rheumatology outpatient department in teaching
hospital.
Participants 209 consecutive patients with rheumatoid arthritis
for over two years; 68 (65%) in the direct access group and 52
(50%) in the control group completed the study (P = 0.04).
Main outcome measures Clinical outcome: pain, disease
activity, early morning stiffness, inflammatory indices, disability,
grip strength, range of movement in joints, and bone erosion.
Psychological status: anxiety, depression, helplessness, self
efficacy, satisfaction, and confidence in the system. Number of
visits to hospital physician and general practitioner for arthritis.
Results Participants were well matched at baseline. After six
years there was only one significant difference between the two
groups for the 14 clinical outcomes measured (deterioration in
range of movement in elbow was less in direct access patients).
There were no significant differences between groups for
median change in psychological status. Satisfaction and
confidence in the system were significantly higher in the direct
access group at two, four, and six years: confidence 9.8 v 8.4, 9.4
v 8.0, 8.7 v 6.9; satisfaction 9.3 v 8.3, 9.3 v 7.7, 8.9 v 7.1 (all
P < 0.02). Patients in the direct access group had 38% fewer
hospital appointments (median 8 v 13, P < 0.0001).
Conclusions Over six years, patients with rheumatoid arthritis
who initiated their reviews through direct access were clinically
and psychologically at least as well as patients having traditional
reviews initiated by a physician. They requested fewer
appointments, found direct access more acceptable, and had
more than a third fewer medical appointments. This radical
responsive management could be tested in other chronic
diseases.
Introduction
Patients with chronic inflammatory diseases such as asthma,
inflammatory bowel disease, and rheumatoid arthritis are
traditionally managed by regular hospital reviews initiated by a
physician. Prebooked reviews may occur when the patient is well
and little action is taken.1 The volume of appointments leads to
an unwieldy system struggling to respond rapidly to requests for
help in the face of fluctuating disease.
General practitioners believe that for such patients rapid
specialist access in times of need is more important than routine
hospital follow up,2 3 but hospital specialists may be reluctant to
relinquish routine reviews.4 A study exploring the use of other
professionals for routine reviews in asthma suggested that
reviews had simply been moved into primary care,5 while a ran-
domised controlled trial in rheumatoid arthritis showed other
professionals could be effective.6
Lengthening periods between reviews or increasing dis-
charge rates7 make some impact but do not address the
fundamental belief that lifelong review is necessary and should
be medically driven. Patients with chronic disease manage their
condition every day and initiate appointments with their general
practitioners when they are unwell, therefore hospital reviews
initiated by the patient could be considered. This might reduce
unnecessary reviews, increase capacity for rapid response to dis-
ease flares, and empower patients.8 Randomised controlled trials
of such “open access” in inflammatory bowel disease found no
clinical detriment but no saving in resources,9 while patients with
ulcerative colitis managed their condition more rapidly in a cri-
sis and requested fewer reviews.10
Rheumatoid arthritis is a chronic disease with unpredictable
periods of inflammatory activity, culminating in disability, bone
erosion, reduced range of movement, and fluctuating pain and
psychological distress.11 Patients have lifelong hospital reviews,
initiated by rheumatologists every three to six months, which
form about three quarters of a rheumatologist’s workload.12
Rheumatoid arthritis is therefore an appropriate disease to test a
new system of access to review in chronic illnesses that use con-
siderable NHS resources.13 14 A two year randomised controlled
trial of the two types of review (initiated by patient or by rheuma-
tologist) found that direct access was safe, cost effective, and
appreciated,15 and findings were maintained at four years.16 To
date, only short term effects of alternative access systems have
been studied, but patients with chronic disease who do not have
routine reviews may have long term physical consequences (they
may not notice gradual physical changes that will go untreated)
and therefore long term studies are required.
We extended the two year trial15 to six years to see whether
such patients show an improvement in clinical and psychological
outcome, reduce their overall use of healthcare resources, and
have greater satisfaction with care compared with patients
receiving traditional review initiated by a rheumatologist.
Two tables of extra data can be found on bmj.com
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Methods
We originally invited consecutive patients who had had rheuma-
toid arthritis for more than two years and who were attending for
routine outpatient reviews to participate in a two year
randomised controlled trial, irrespective of clinical status.
Randomisation was performed blind, using computer generated
numbers concealed in envelopes prepared by an independent
party. If patients agreed to participate we then sought consent
from their general practitioners. Patients who took part in the
two year study were afterwards invited to continue the study for a
further four years.
Access to care
Patients in the group in which review was initiated by the patient
(direct access) were not offered routine hospital reviews, and
their general practitioners were given a short leaflet to support
day to day management of patients. Patients (or general
practitioners) arranged reviews with a rheumatologist, physi-
otherapist, or occupational therapist through a nurse-led
telephone helpline. Fortnightly direct access clinics gave a maxi-
mum delay of 10 working days before appointments, though
patients could receive immediate advice from a nurse.
Patients in the control group continued with traditional hos-
pital reviews ordered by the rheumatologist every three to six
months according to normal practice, and, as usual, requests for
urgent reviews were made by general practitioners through the
secretary and accommodated as quickly as possible. At each
appointment patients in both groups were managed according
to clinical need.
Outcome measures
Clinical status—Each year we assessed pain and the patients’
opinion of disease activity (10 cm visual analogue scales), early
morning stiffness, and disability (health assessment question-
naire)17 by postal questionnaires. At four, five, and six years we
added a generic quality of life measure (SF-36).18 Every two years
(baseline and two, four, and six years) we assessed plasma viscos-
ity, C reactive protein, haemoglobin concentration, grip strength,
range of movement (elbows and knees), and bony erosions (hand
x ray films). Case notes were independently reviewed at two years
(covering baseline to two years) and six years (covering four to six
years) to assess complications of rheumatoid arthritis.
Psychological status—We also carried out annual postal assess-
ments of anxiety and depression (hospital anxiety and
depression scale),19 helplessness (arthritis helplessness index
subscale),20 self efficacy (arthritis self efficacy scales),21 and
satisfaction with and confidence in the system (10 cm visual ana-
logue scales).
Appointment use—We recorded all visits to hospital rheuma-
tologists and visits to general practitioners for problems related
to arthritis. During the two year study there was no difference
between the groups in visits to occupational therapy and to
physiotherapy15 so we did not measure these in the extension
period.
Statistical analysis
The original two year randomised controlled trial was designed
to show a difference of 12% in pain at 95% power (n = 186),22 and
182 datasets were completed.15 The extension to six years gave
120 completed datasets, which reduced the power to 81%. As
most outcome measures had skewed distributions, we used
medians, interquartile ranges (first and third), and non-
parametric tests. We summarised differences between the two
groups over time using both the median change from baseline to
six years and the area under the curve for repeated observations
at baseline and at two, four, and six years (trapezoidal rule) and
tested them with the Mann-Whitney U test (applying the
Kruskal-Wallis test first when we compared multiple groups)
with a two tailed significance at the 5% level. Seventy four
patients had x ray films at baseline and six years (39 direct access,
35 controls) assessed by the Larsen index (sum of the 14 joint
damage scores of each hand, plus two wrist scores weighted by
5).23 24 We used the Townsend deprivation score as a measure of
socioeconomic status.25
Results
Of 302 patients invited to participate, 209 agreed. Patients who
declined were significantly older than those who participated
(median 69 years v 58 years, P < 0.05) and more disabled
(median score on health assessment questionnaire 2.2 v 1.5,
P < 0.05. At six years 120 patients remained for analysis (68
(65%) in direct access group and 52 (50%) in control group,
P = 0.04) (fig 1). Thirty patients died (12 in the direct access
group and 18 in the control group). Using the last observation,
we found no significant difference or strong directional trend for
clinical or psychological outcomes between the groups for those
who died. Because those who died were significantly older at
baseline (median difference 10 years) and many outcomes were
related to age, we excluded these patients from further compari-
son. The 59 surviving patients who did not complete the study
(direct access 25, control 34) were similar at baseline to those
who completed the study, differing only for longer duration of
disease and less range of movement (table 1).
The 120 patients (direct access 68, control 52) who formed
the final dataset differed at baseline only for stronger grip
strength in the direct access group (table 1). The Townsend dep-
rivation score25 was not significantly different between groups
Invited to participate (n=302)
Agreed to participate (n=209)
Randomised to direct
access group (n=105)
Did not complete (n=12)
(8 declined, 1 general
practitioner declined,
3 files lost)
Did not complete (n=15)
(14 declined, 1 died)
Randomised to
control group (n=104)
Analysis at two years (n=93) Analysis at two years (n=89)
Did not complete (n=19)
(4 declined, 8 died, 4 ill,
1 moved, 1 discharged,
1 rediagnosed)
Did not complete (n=29)
(10 declined, 11 died,
3 ill, 5 moved)
Analysis at four years (n=74) Analysis at four years (n=60)
Did not complete (n=6)
(2 declined, 4 died)
Did not complete (n=8)
(2 declined, 6 died)
Analysis at six years (n=68) Analysis at six years (n=52)
Fig 1 Study flowchart
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(median score –0.1, (interquartile range –2.4 to 3.3) v –0.2 (–1.8
to 3.1), respectively).
Clinical outcome at six years—There were no significant differ-
ences between the groups in median change scores for clinical
outcome (table 2), except for range of movement in the elbow,
where the direct access group deteriorated less. Quality of life at
four and six years was not significantly different between the
groups, except for a greater deterioration in physical function in
the direct access group (SF-36: direct access − 5, control 0,
P = 0.04, see table A on bmj.com), which was not shown in the
disability measure specific for arthritis (health assessment
questionnaire, table 2). Complications (respiratory or renal
involvement, vasculitis, anaemia, drug reactions, gastrointestinal
problems) and need for joint surgery were not significantly
different between the groups (4 v 5 patients over baseline to two
years and 16 v 17 patients over four to six years, P = 0.36).
Psychological status and satisfaction with the system—There were
no significant differences between the groups over the six years
for median change in any of the psychological variables (table 2).
There were no differences between the groups for satisfaction
with and confidence in the traditional system of care at baseline
(table 1), but both were significantly higher for the direct access
system thereafter (fig 2), and at six years both had decreased by
10% in the control group (table 2). General practitioners’
satisfaction and confidence in the system at six years was higher
for direct access (satisfaction: 8.4 (7.5-9.6) v 7.5 (5.5-8.57),
P = 0.005; confidence: 8.4 (7.25-9.45) v 8.0 (5.72-8.7), P = 0.04).
Clinical and psychological results were replicated in analysis
according to area under the curve (see table B on bmj.com).
Appointments with rheumatologist and general practitioners—
Direct access patients had 38% fewer hospital reviews over six
years (median 8 (5-13) v 13 (11-17), P < 0.0001) with 34% of
direct access patients receiving more than 10 hospital reviews
compared with 85% of control patients (fig 3). Fourteen direct
access patients (21%) did not request an appointment during the
first two years, 19 (28%) during years two to four, and 14 (21%)
during years four to six. This includes three patients who did not
request any appointments over the six years. During years four to
six we recorded the intervals between patients’ requests and sub-
sequent appointments. These were not different between groups
(direct access requested 166 appointments, median delay 6 days,
3-9; controls requested 10 additional appointments, median 8
days, 4.5-11.25). The number of visits to the general practitioner
for consultations about arthritis was not significantly different
between the groups over the six years (median 8, 3-20; v 9.5,
3-17).
Discussion
Patients using direct access for hospital review of their rheuma-
toid arthritis fare as well clinically and psychologically over six
years as patients receiving traditional review initiated by a rheu-
Table 1 Baseline characteristics (excluding deaths). Figures are medians (interquartile range) unless stated otherwise
Did not complete study (n=59)
Completed study (n=120)
P value*
Direct access group Control group
No of
patients Median (IQ range)
No of
patients Median (IQ range)
No of
patients Median (IQ range)
Age (years) 59 55 (46.0 to 66.0) 68 58.0 (48.3 to 65.0) 52 57.0 (48.3 to 66.0) 0.91
Disease duration (years) 43 13† (6.50 to 22.0) 65 7.0 (4.0 to 13.0) 51 10.0 (5.0 to 14.0) 0.01
% female 59 74.6% 68 66.2% 52 71.1% 0.58
Outcome measure scale
Pain (0-10)‡ 48 2.60 (1.50 to 4.90) 68 3.00 (1.73 to 5.58) 52 3.10 (1.42 to 4.80) 0.87
Early morning stiffness
(0-1440 min)‡
48 22.5 (4.30 to 60.0) 68 30.0 (10.0 to 60.0) 52 30.0 (10.0 to 60.0) 0.49
CRP (<10-200 mg/l)‡ 52 15.0 (10.0 to 26.8) 60 11.5 (10.0 to 22.8) 46 10.0 (10.0 to 19.5) 0.08
PV (1.5-2.7 mPa )‡ 52 1.74 (1.67 to 1.06) 61 1.73 (1.67 to 1.76) 48 1.73 (1.63 to 1.79) 0.12
Haemoglobin (50-170 g/l )§ 53 124 (115 to 133) 61 125 (125 to 138) 48 125 (118 to 131) 0.28
Disability (HAQ) (0-3)‡ 47 1.50 (1.00 to 2.25) 68 1.25 (0.625 to 1.875) 52 1.375 (0.625 to 1.875) 0.19
Grip strength (0-72 kg)§:
Right hand 51 10.0 (8.0 to 18.0) 66 15.0†(9.5 to 26.5) 51 10.0 (8.0 to 20.0) 0.04
Left hand 52 10.0 (6.0 to 18.0) 66 18.0† (10.0 to 26.0) 51 10.0 (8.0 to 20.0) 0.0002
Range of movement (elbow 0-150°, knee 0-140°)§:
Right elbow 53 120† (105 to 138) 67 133 (120 to 140) 51 137 (120 to 143) 0.007
Left elbow 54 125† (100 to 140) 67 135 (125 to 142) 51 137 (125 to 148) 0.02
Right knee 51 105† (87 to 120) 66 115 (105 to 123.3) 51 117 (105 to 124) 0.02
Left knee 52 113 (90 to 124) 66 119 (105 to 125) 51 115 (103 to 126) 0.17
Larsen index, both hands
(0-190)‡
— — 39 39 (21 to 68) 35 37 (5 to 55) 0.15
Anxiety (0-21)‡ 47 6.0 (3.0 to 9.0) 68 7.0 (4.0 to 10.0) 52 7.0 (5.0 to 9.0) 0.40
Depression (0-21)‡ 47 4.0 (3.0 to 7.0) 68 5.0 (2.0 to 7.0) 52 4.5 (2.0 to 7.8) 0.88
Helplessness (5-30)‡ 47 18.0 (14.0 to 21.0) 68 16.5 (14.0 to 19.3) 52 16.0 (12.0 to 19.0) 0.21
Self efficacy (10-100)§:
Pain 47 62.0 (44.0 to 76.0) 67 58.0 (46.0 to 70.0) 50 50.0 (34.0 to 66.2) 0.12
Function 46 62.0 (35.0 to 83.0) 66 67.3 (45.0 to 86.7) 50 62.2 (44.1 to 81.4) 0.45
Other 47 68.0 (47.0 to 82.0) 67 70.0 (53.3 to 80.0) 49 70.0 (50.9 to 80.0) 0.92
Satisfaction (0-10)§ 46 8.8 (7.2 to 9.7) 62 8.9 (7.3 to 9.7) 50 8.9 (7.6 to 9.6) 0.99
Confidence (0-10)§ 47 9.3 (8.4 to 9.6) 62 9.3 8.0 to 9.6) 50 8.9 6.7 to 9.5) 0.24
CRP=C reactive protein, PV=plasma viscosity, HAQ=health assessment questionnaire.
*Kruskal-Wallis test except for sex, where 2 used with Yates’s correction on 2 df.
†Significant difference between the groups at 5% level.
‡Lower scores indicate better health.
§Higher scores indicate better health.
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matologist, but use fewer appointments and are more satisfied
with and confident in their system of care.
Limitations
The 93 patients who declined to participate were older and had
greater disability, possibly suggesting that such patients may be
less amenable to change (data not collected). After randomisa-
tion more control than direct access patients withdrew, and
repeated questionnaires and research visits in the absence of
perceived benefit may have been a disincentive to those in the
control group. Patients who withdrew had had rheumatoid
arthritis for longer and less range of movement at baseline, but
outcome data available at two years showed no major differences
compared with those who completed the study (data not shown).
Changes in clinical and psychological outcomes in those
using direct access were no different over six years to changes in
patients using traditional reviews initiated by a rheumatologist.
Range of movement in the elbow deteriorated less in the direct
access group but goniometry measurements can be imprecise.
Table 2 Median changes in outcome from baseline to six years
Measurement*
Direct access group Control group
P value*No of patients Median change (IQ range) No of patients Median change (IQ range)
Clinical measures
Pain (0-10)† 68 1.25 (−0.40 to 3.25) 52 1.1 (−1.00 to 3.60) 0.91
Disease activity (0-10)† 68 0.25 (−1.35 to 2.80) 52 0.25 (−0.88 to 2.80) 0.49
Early morning stiffness (0-1440 mins)† 68 0 (−10.0 to 33.0) 52 5.0 (−15.0 to 20.0) 0.80
CRP (<10-200 mg/l)† 58 −0.95 (−12.0 to 20.5) 39 −3.00 (−8.4 to 3.0) 0.62
PV (1.5-2.7 mPa)† 58 0.07 (−0.01 to 0.14) 42 0.07 (−0.04 to 0.16) 0.78
Haemoglobin (50-170 g/l)‡ 59 0 (−6 to 9) 44 2 (−5.5 to 7.8) 0.39
Disability (HAQ) (0-3)† 68 0.19 (−0.125 to 0.75) 51 0.25 (0 to 0.75) 0.39
Grip strength (0-72 kg)‡:
Right hand 65 −4.0 (−10 to 0) 49 −2.0 (−5.5 to 2.0) 0.13
Left hand 65 −4.0 (−10 to 0) 49 −1.0 (−7.0 to 0) 0.07
Range of movement (elbow 0-150°, knee 0-140°)‡:
Right elbow 63 −17.0§ (−35.0 to 0) 50 −25.5 (−40.5 to –14.5) 0.04
Left elbow 63 −15.0§ (−25.0 to 0) 50 −24.5 (−40.3 to –4.0) 0.02
Right knee 62 −4.0 (−20.0 to 7.0) 47 −8.0 (−30.0 to 7.0) 0.60
Left knee 62 −5.0 (−20.0 to 5.0) 46 −8.5 (−26.3 to –8.5) 0.65
Larsen index, both hands (0-190)† 39 14 (0 to 27) 35 9 (2 to 23) 0.69
Psychological measures
Anxiety (0-21)† 68 0 (−2.0 to 3.0) 52 0 (−2.0 to 3.0) 0.95
Depression (0-21)† 68 0 (−1.0 to 3.0) 52 0 (−1.0 to 2.75) 0.80
Helplessness (5-30)† 66 0.5 (−3.0 to 3.0) 52 1.0 (−1.75 to 4.0) 0.20
Self efficacy (10-100)‡:
Pain 67 2.0 (−12.0 to 16.0) 50 1.0 (−10.0 to 19.0) 0.49
Function 66 −2.75 (−15.9 to 5.0) 50 −6.6 (−20.6 to 2.40) 0.19
Other 67 −3.30 (−11.6 to 8.3) 49 −6.7 (−15.0 to 6.7) 0.25
Satisfaction (0-10)‡ 62 0§ (−0.7 to 0.9) 49 −1.1 (−2.70 to 0.25) 0.0004
Confidence (0-10)‡ 62 −0.15§ (−0.73 to 0.43) 49 −1.0 (−2.35 to 0.20) 0.0005
*Mann Whitney U test.
†Lower scores indicate better health.
‡Higher scores indicate better health.
§Significant difference between two groups at 5% level.
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The complication rate was not significantly different between
groups, but the number of complications and need for surgery
seemed to increase in both groups during the latter part of the
study, perhaps because by then patients had had the disease for
longer or because different assessors had to be used at the two
time points. Patients’ satisfaction and confidence were high for
both systems but diminished in patients in the control group
over the six years.
Direct access patients had 38% fewer appointments with a
rheumatologist than patients in the control group. Some direct
access patients requested few or even no appointments, and the
research visits at two, four, and six years may have acted as a
safety net for them. In the clinical direct access service
established in our trust after this trial, patients who have not
requested an appointment in the previous two years are
reviewed by a nurse specialist. After excluding pure research vis-
its from our data, we calculate that an average of 11% of direct
access patients each year will not request a review. Some costs are
needed to set the service up (organising education of patients,
helpline, nurse reviews, general practitioner guidelines, appoint-
ment systems), but in the longer term, resources released by
fewer appointments with a rheumatologist should offset this ini-
tial investment.
The power of the study inevitably declined over six years, but
overall, out of 22 outcomes, 12 were more favourable for direct
access patients (four significantly) compared with only six
favouring control patients (none significantly). It is possible that
with a larger population of patients completing to six years, some
of these borderline differences might have reached significance,
and those seen at two years (pain and self efficacy)15 might have
been maintained.
Blinding of patients, the physician, and assessors to group
allocation was not possible, giving the potential for bias. The
study patients, however, formed a minority of the physician’s
caseload, and it is unlikely that a systematically different
approach to these 120 patients was maintained for six years,
while the use of a single physician minimised the confounding
variable of differing clinical management. Patients and assessors
completed validated standardised outcome measures and would
be unlikely to be able to maintain a consistent bias.
Differences to other studies
This study differs importantly from others in that it uses direct
access to replace rather than complement routine review and the
key point of access is clinical, not administrative. It shows poten-
tial resource savings rather than transferring resources to
primary care, and the results can be maintained without clinical
detriment in the long term. Forthcoming analyses will address
other important questions, including the timing and efficacy of
appointments by using additional clinical data collected during
years four to six, and assessing missed clinical need by analysing
a combined review from the occupational therapist and
physiotherapist of a random sample of patients at six years.
This trial used consecutive patients with rheumatoid arthritis
and should therefore be generalisable, but local issues (patients,
staff, administrative) may influence systems and outcomes, there-
fore a multi-centre study with various hospital settings is needed
to ascertain the generalisability of direct access. Other research
could explore the altered roles of general practitioners, hospital
physicians,26 patients, and nurses in management of chronic dis-
ease.
Conclusions
The traditional system of routine hospital follow up in chronic
disease is a drain on NHS resources and a burden for patients if
they are well. Direct access initiated by patients challenges the
traditional view that medically driven regular hospital review is
required and reduces the volume of perhaps unnecessary
reviews, while targeting them to support clinical need and reflect
the NHS commitment to the “expert patient.”8 If this system was
instigated on a large scale, the resources released could be used
to improve care in other ways (for example, by reducing waiting
times for new patients) or to increase the overall throughput of
outpatients (by supporting up to a third more patients). Further-
more, this model could be tested in other chronic inflammatory
illnesses that encompass a degree of self management, such as
asthma, diabetes, and inflammatory bowel disease.
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